Injective (INJ) is currently trading at $3.01, reflecting a 3.57% increase over the past 24 hours, indicating a mild bullish sentiment. The asset has oscillated between a 24-hour high of $3.06 and a low of $2.91, showcasing a daily range of 5.14%, which suggests some volatility in the short term.

Volume stands at approximately 49.99 million, with a volume-to-market cap ratio of 16.62%, indicating healthy trading activity relative to its market capitalization. The hourly moving averages show mixed signals, with the 8 SMA and 13 SMA declining, while the 21 SMA and longer-term SMAs are trending upwards, suggesting potential consolidation around the current price level.

The 1-hour RSI at 38 indicates that INJ is approaching oversold territory, while the 7-day RSI at 53 reflects a neutral stance, implying that there is potential for a reversal if buying pressure increases. Over the past week, INJ has seen a price change of approximately 5.92%, indicating a short-term recovery, while the 30-day change of -2.05% shows longer-term weakness.

The all-time high of $52.62 reached in March 2024 indicates significant long-term potential, but the current price level is far below that peak. Investors should note the recent positive price movements in the context of a longer-term downtrend, as evident from the 30-day change.

Based on the current analysis, I recommend a Hold rating for Injective (INJ). While there are short-term bullish indicators, the overall trend remains bearish in the longer context, warranting caution before committing additional capital. Monitoring for a confirmed breakout above the current resistance level near $3.06 could provide a more favorable entry point.